Results 101 to 110 of about 42,703 (308)

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. [PDF]

, 2009
The approach to treating autoimmune disorders is currently undergoing a significant change in focus. As therapies are developed that are more precise in targeting the pathogenesis for these diseases, patients experience significantly fewer side effects ...
Sands, Jacob, Tuscano, Joseph M
core   +2 more sources

Health-related quality of life and depression among participants in the Sjögren's International Collaborative Clinical Alliance registry. [PDF]

, 2017
ObjectiveTo examine health-related quality of life (HRQoL) and depression among participants in an international Sjögren's syndrome (SS) registry, comparing those with and without SS.MethodsCross-sectional study of participants in the Sjögren's ...
Chou, Annie, Criswell, Lindsey A, Daniels, Troy E, Gonzales, John A, Shiboski, Caroline H, Shiboski, Stephen C   +5 more
core   +1 more source

Identifying Predictive Biomarkers of Response in Patients With Rheumatoid Arthritis Treated With Adalimumab Using Machine Learning Analysis of Whole‐Blood Transcriptomics Data

Arthritis &Rheumatology, EarlyView.
Objective Tumornecrosis factor inhibitors (TNFi) have significantly improved rheumatoid arthritis (RA) management, yet variability in patient response remains a substantial challenge, with approximately 40% of patients discontinuing TNFi due to nonresponse or adverse effects.
Chuan Fu Yap, Nisha Nair, Ann W. Morgan, John D. Isaacs, Anthony G. Wilson, Kimme Hyrich, Guillermo Barturen, María Riva‐Torrubia, Marta Gut, Ivo Gut, Marta E. Alarcón Riquelme, Anne Barton, Darren Plant   +12 more
wiley   +1 more source

Disease-modifying antirheumatic drugs – Old and new: A brief overview

Clinical Dermatology Review, 2019
Rheumatological disorders comprise a vast subset of conditions with differing manifestations but overlap in pathogenesis. Disease-modifying antirheumatic drugs (DMARDs) are a diverse group of medications which aim at the various pathogenic factors ...
Vidya Divakar Baliga, Raghuveer S Prabhu
doaj   +1 more source

Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries : are differences related to country's wealth? [PDF]

, 2014
Objectives: To explore criteria regulating treatment with reimbursed biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) across Europe and to relate criteria to indicators of national socioeconomic welfare.
Boonen, Annelies, Equity in Clinical Eligibility Criteria for RA treatment Working group, on behalf of, Kvien, Tore K, Mielants, Herman, Putrik, Polina, Ramiro, Sofia, Sokka, Tuulikki, Uhlig, Till   +7 more
core   +2 more sources

Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Course of Interstitial Lung Disease in Patients With Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective We used data from the placebo arm of the Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial to determine the prognostic/predictive significance of peripheral blood cell (PBC) transcript modules for the course of forced vital capacity (FVC) in patients with systemic sclerosis–associated interstitial lung disease (SSc‐ILD ...
Shervin Assassi, Christopher P. Denton, Matthias Zwick, Ramona Schmid, Carina Ittrich, Tobias Litzenburger, Sudha Visvanathan   +6 more
wiley   +1 more source

Advances in the Drugs Treatment of Psoriatic Arthritis

Xiehe Yixue Zazhi
Psoriatic arthritis (PsA), an inflammatory articular disease closely associated with psoriasis, is characterized by a wide range of symptoms including skin lesion, peripheral and axial joint involvement, enthesitis, and dactylitis.
LU Chaofan, LENG Xiaomei
doaj   +1 more source

Impact of Interleukin‐1 Blockade on the Development of Macrophage Activation Syndrome in Still Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the applicability of the 2016 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR)/Paediatric Rheumatology International Trials Organisation (PRINTO) macrophage activation syndrome (MAS) classification criteria in patients with Still disease and systemic juvenile idiopathic arthritis ...
Remco G. A. Erkens, Greta Rogani, Laura Huber, Anouk Verwoerd, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Wineke Armbrust, G. Elizabeth Legger, Sylvia Kamphuis, Ellen J. H. Schatorjé, Esther P. A. H. Hoppenreijs, Joost F. Swart, Marc H. A. Jansen, Jorg van Loosdregt, Sebastiaan J. Vastert   +14 more
wiley   +1 more source

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Health Technology Assessment, 2011
Background: Rheumatoid arthritis (RA) is an inflammatory condition that typically causes a symmetrical chronic arthritis. Timely use of disease-modifying antirheumatic drugs (DMARDs) is an essential aspect of disease management, but many patients may not
K Malottki, P Barton, A Tsourapas, AO Uthman, Z Liu, K Routh, M Connock, P Jobanputra, D Moore, A Fry-Smith, Y-F Chen   +10 more
doaj   +1 more source

Therapeutic Drug Monitoring (TDM) in The Use of Aspirin as Antirheumatoid Drugs

Sains Medika, 2012
Therapeutic drug monitoring (TDM) is used in drug therapy for selected drugs with narrow therapeutic index, or a broad range of kinetics variation, or drugs with strong correlation between plasma concentration and clinical effects or toxicity. Aspirin is
Isnatin Miladiyah
doaj   +1 more source